Highlights from: The 2008 meeting of the American Society of Clinical Oncology; May 30-June 3, 2008; Chicago, IL.
暂无分享,去创建一个
[1] Mitch Dowsett,et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] T. Yap,et al. Targeting CYP17: established and novel approaches in prostate cancer. , 2008, Current opinion in pharmacology.
[3] J. Witjes,et al. Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): Overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial , 2008 .
[4] S. Steinberg,et al. Randomized phase III trial of thalidomide (Th) or placebo (P) for non-metastatic PSA recurrent prostate cancer (PCa) treated with intermittent therapy , 2008 .
[5] M. Dowsett,et al. Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC) , 2008 .
[6] R. Figlin,et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) , 2008 .
[7] C. Porta,et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC)after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter Phase-III study , 2008 .
[8] L. Schwartz,et al. Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy , 2008 .
[9] R. Figlin,et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors , 2007 .
[10] C. Sternberg,et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial , 2007 .
[11] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[12] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[13] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[14] R. Amato,et al. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Motzer,et al. Sunitinib in patients with metastatic renal cell carcinoma. , 2006, JAMA.
[16] H. Scher,et al. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] C. Sternberg. Satraplatin in the treatment of hormone‐refractory prostate cancer , 2005, BJU international.
[18] L. Collette,et al. Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer , 2005, Oncology.
[19] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[20] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[21] S. Steinberg,et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] I Judson,et al. Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer , 2004, British Journal of Cancer.
[23] S. Steinberg,et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] J. Moul,et al. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. , 1998, The Journal of urology.
[25] W. Figg,et al. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. , 1998, Biochemical pharmacology.
[26] P. Stattin,et al. Vascular density is a predictor of cancer‐specific survival in prostatic carcinoma , 1997, The Prostate.
[27] R. Fisher,et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] R. D'Amato,et al. Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[29] W Blumenfeld,et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.
[30] L. Kèlland,et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. , 1993, Cancer research.
[31] R. Figlin,et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] David C. Smith,et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC) , 2004, Investigational New Drugs.
[33] R. Motzer,et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.